{"id":3868,"date":"2017-02-04T10:45:03","date_gmt":"2017-02-04T10:45:03","guid":{"rendered":"https:\/\/www.sygnaturediscovery.com\/poster\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\/"},"modified":"2025-12-12T11:35:00","modified_gmt":"2025-12-12T11:35:00","slug":"adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes","status":"publish","type":"poster","link":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\/","title":{"rendered":"Adoption of High Content Imaging Capabilities in Support of Integrated Drug Discovery Programmes"},"content":{"rendered":"

Sygnature Discovery is the UK’s largest independent provider of integrated drug discovery resources and expertise. We undertake hit identification, hit-to-lead and lead optimisation projects and complete drug discovery programs across a range of therapeutic areas. In support of this, we have expanded our assay capability to include the state-of-the-art ImageXpress(R) Micro COnfocal (IXM-C) high-content imaging platform to provide multi-dimensional, high-throughput screening solutions to facilitate in-house drug profiling, bioscience and DMPK in vitro<\/em> activities. Here we demonstrate the application of our integrated imaging platforms including the IXM-C and associated MetXppress(R) Image acquisition and analysis software to multiple phases of the drug discovery process.<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"featured_media":2500,"template":"","category":[1],"class_list":["post-3868","poster","type-poster","status-publish","has-post-thumbnail","hentry","category-uncategorized"],"acf":[],"yoast_head":"\nHigh Content Imaging for Integrated Drug Discovery at Sygnature<\/title>\n<meta name=\"description\" content=\"Offering state-of-the-art imaging platforms for high-throughput screening and drug profiling across various therapeutic areas.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"High Content Imaging for Integrated Drug Discovery at Sygnature\" \/>\n<meta property=\"og:description\" content=\"Offering state-of-the-art imaging platforms for high-throughput screening and drug profiling across various therapeutic areas.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\/\" \/>\n<meta property=\"og:site_name\" content=\"Sygnature\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-12T11:35:00+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Screen-Shot-2018-03-08-at-10.34.29.png\" \/>\n\t<meta property=\"og:image:width\" content=\"796\" \/>\n\t<meta property=\"og:image:height\" content=\"1128\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\\\/\",\"name\":\"High Content Imaging for Integrated Drug Discovery at Sygnature\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Screen-Shot-2018-03-08-at-10.34.29.png\",\"datePublished\":\"2017-02-04T10:45:03+00:00\",\"dateModified\":\"2025-12-12T11:35:00+00:00\",\"description\":\"Offering state-of-the-art imaging platforms for high-throughput screening and drug profiling across various therapeutic areas.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Screen-Shot-2018-03-08-at-10.34.29.png\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Screen-Shot-2018-03-08-at-10.34.29.png\",\"width\":796,\"height\":1128,\"caption\":\"Adoption of High Content Imaging Capabilities in Support of Integrated Drug Discovery Programmes\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/page-daccueil\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Adoption of High Content Imaging Capabilities in Support of Integrated Drug Discovery Programmes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"name\":\"Sygnature Discovery\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\"},\"alternateName\":\"Sygnature\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\",\"name\":\"Sygnature\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"width\":1,\"height\":1,\"caption\":\"Sygnature\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"High Content Imaging for Integrated Drug Discovery at Sygnature","description":"Offering state-of-the-art imaging platforms for high-throughput screening and drug profiling across various therapeutic areas.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\/","og_locale":"fr_CA","og_type":"article","og_title":"High Content Imaging for Integrated Drug Discovery at Sygnature","og_description":"Offering state-of-the-art imaging platforms for high-throughput screening and drug profiling across various therapeutic areas.","og_url":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\/","og_site_name":"Sygnature","article_modified_time":"2025-12-12T11:35:00+00:00","og_image":[{"width":796,"height":1128,"url":"http:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Screen-Shot-2018-03-08-at-10.34.29.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimation du temps de lecture":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\/","url":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\/","name":"High Content Imaging for Integrated Drug Discovery at Sygnature","isPartOf":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\/#primaryimage"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Screen-Shot-2018-03-08-at-10.34.29.png","datePublished":"2017-02-04T10:45:03+00:00","dateModified":"2025-12-12T11:35:00+00:00","description":"Offering state-of-the-art imaging platforms for high-throughput screening and drug profiling across various therapeutic areas.","breadcrumb":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sygnaturediscovery.com\/fr\/poster\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\/"]}]},{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\/#primaryimage","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Screen-Shot-2018-03-08-at-10.34.29.png","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Screen-Shot-2018-03-08-at-10.34.29.png","width":796,"height":1128,"caption":"Adoption of High Content Imaging Capabilities in Support of Integrated Drug Discovery Programmes"},{"@type":"BreadcrumbList","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sygnaturediscovery.com\/fr\/page-daccueil\/"},{"@type":"ListItem","position":2,"name":"Adoption of High Content Imaging Capabilities in Support of Integrated Drug Discovery Programmes"}]},{"@type":"WebSite","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","name":"Sygnature Discovery","description":"","publisher":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization"},"alternateName":"Sygnature","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sygnaturediscovery.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization","name":"Sygnature","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","width":1,"height":1,"caption":"Sygnature"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/poster\/3868","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/poster"}],"about":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/types\/poster"}],"version-history":[{"count":0,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/poster\/3868\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media\/2500"}],"wp:attachment":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media?parent=3868"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/category?post=3868"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}